Invivyd (NASDAQ:IVVD) Receives "Buy" Rating from D. Boral Capital

Invivyd (NASDAQ:IVVD - Get Free Report)'s stock had its "buy" rating reissued by analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports. They presently have a $9.00 target price on the stock.

Several other brokerages have also weighed in on IVVD. Morgan Stanley cut their price objective on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating on the stock in a report on Wednesday, November 20th. HC Wainwright cut their price objective on shares of Invivyd from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I upgraded shares of Invivyd to a "strong-buy" rating in a report on Wednesday, October 30th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Invivyd has an average rating of "Buy" and an average price target of $7.89.

Invivyd Price Performance

Shares of IVVD stock traded down $0.01 during trading hours on Friday, reaching $0.45. 13,638,793 shares of the company were exchanged, compared to its average volume of 3,388,904. Invivyd has a fifty-two week low of $0.40 and a fifty-two week high of $5.20. The stock's fifty day moving average is $0.64 and its two-hundred day moving average is $0.91. The company has a market cap of $54.07 million, a price-to-earnings ratio of -0.23 and a beta of 0.64.

Insider Buying and Selling at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 150,000 shares of the company's stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $0.61, for a total value of $91,500.00. Following the completion of the sale, the director now owns 4,538,079 shares of the company's stock, valued at approximately $2,768,228.19. This represents a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders sold 816,466 shares of company stock valued at $423,214. Corporate insiders own 17.90% of the company's stock.

Institutional Investors Weigh In On Invivyd

Large investors have recently made changes to their positions in the stock. Proficio Capital Partners LLC bought a new stake in shares of Invivyd during the third quarter worth $27,000. XTX Topco Ltd increased its position in shares of Invivyd by 68.1% during the second quarter. XTX Topco Ltd now owns 37,938 shares of the company's stock worth $42,000 after acquiring an additional 15,376 shares in the last quarter. Cornercap Investment Counsel Inc. bought a new stake in shares of Invivyd during the second quarter worth $86,000. Rhumbline Advisers increased its position in shares of Invivyd by 4,434.1% during the second quarter. Rhumbline Advisers now owns 84,017 shares of the company's stock worth $92,000 after acquiring an additional 82,164 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Invivyd during the second quarter worth $115,000. Institutional investors own 70.36% of the company's stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.